Current problems in cancer. Case reports最新文献

Adeno-squamous carcinoma of bartholin gland: Challenges in diagnosis and management of a less known vulvar cancer – A case report 巴氏腺鳞癌：鲜为人知的外阴癌的诊断和治疗难题 - 病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100330

引用次数: 0

Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report 延长 EGFR-L858R NSCLC 术后复发患者的生存期：长达 24 年的病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100329

引用次数: 0

Refractory chronic lymphocytic leukemia with concomitant extramedullary multiple myeloma with lymph node involvement 难治性慢性淋巴细胞白血病合并淋巴结受累的髓外多发性骨髓瘤

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100324

引用次数: 0

Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report 化疗当天服用非格司亭预防药物引发过敏性休克：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-17 DOI: 10.1016/j.cpccr.2024.100328

{"title":"Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report","authors":"","doi":"10.1016/j.cpccr.2024.100328","DOIUrl":"10.1016/j.cpccr.2024.100328","url":null,"abstract":"<div><h3>Introduction</h3><div>Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy.</div></div><div><h3>Case presentation</h3><div>We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim.</div></div><div><h3>Conclusion</h3><div>The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Refractory IgM AL amyloidosis with massive soft tissue tumors: Rescue with zanubrutinib. A case report 难治性IgM AL淀粉样变性伴巨大软组织肿瘤：扎努布替尼的救治。病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-12 DOI: 10.1016/j.cpccr.2024.100325

引用次数: 0

Unusual presentation of melena due to duodenal metastasis from primary lung adenocarcinoma 原发性肺腺癌十二指肠转移引起的血性腹泻的异常表现

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-11 DOI: 10.1016/j.cpccr.2024.100326

引用次数: 0

Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series 用卡铂加紫杉醇对无法切除的局部晚期胸腺癌进行确定性化放疗：一个病例系列

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-09-17 DOI: 10.1016/j.cpccr.2024.100323

{"title":"Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series","authors":"","doi":"10.1016/j.cpccr.2024.100323","DOIUrl":"10.1016/j.cpccr.2024.100323","url":null,"abstract":"<div><h3>Objectives</h3><p>Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.</p></div><div><h3>Materials and methods</h3><p>We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.</p></div><div><h3>Results</h3><p>Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m<sup>-12</sup>) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.</p></div><div><h3>Conclusion</h3><p>Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000462/pdfft?md5=fa9d2b295942b0387d1f7cb0dacef82f&pid=1-s2.0-S2666621924000462-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report 在接受化疗放疗的肺癌相关恶病质患者中使用盐酸阿那莫林：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-09-12 DOI: 10.1016/j.cpccr.2024.100322

引用次数: 0

Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report 胰腺尾部肿瘤引发的 Stauffer 综合征：旁分泌型发病机制，而非炎症性免疫失调现象--病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-09-01 DOI: 10.1016/j.cpccr.2024.100320

{"title":"Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report","authors":"","doi":"10.1016/j.cpccr.2024.100320","DOIUrl":"10.1016/j.cpccr.2024.100320","url":null,"abstract":"<div><p>Stauffer syndrome, also known as paraneoplastic intrahepatic cholestasis syndrome, is a rare reversible clinical manifestation characterized by elevation of direct bilirubin, alcaline phosphatase, transaminases and prolonged prothrombin time, without direct hepatobiliary disease, that is due to the presence of malignancy, mostly kidney cancer. In this case report, we describe a rare form of mixed acinar neuroendocrine pancreatic tail mass causing a non-obstructive form of cholestasis. We analysed the effects of metilprednisolone treatment and surgery on the levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha), previously associated with this syndrome. We found that serum levels of IL-6 and TNF alpha decreased during steroid treatment, had a peak immediately after the surgical procedure, and remained stable while cholestasis resolved slowly after tumour removal. These findings showed that IL-6 and TNF alpha were not the effectors of the paraneoplastic cholestasis in our patient. Rather, the evidence of a mixed acinar neuroendocrine pancreatic tumour and non-specific cholestasis at the liver histology suggests paracrine mechanisms affecting cellular transporters implicated in bile acids excretion.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000437/pdfft?md5=abb1c6a23eb67343a69b75ff773faa98&pid=1-s2.0-S2666621924000437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142136275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma 病例报告：浸润性微乳头状瘤原发病灶的异质性

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-09-01 DOI: 10.1016/j.cpccr.2024.100321

{"title":"Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma","authors":"","doi":"10.1016/j.cpccr.2024.100321","DOIUrl":"10.1016/j.cpccr.2024.100321","url":null,"abstract":"<div><p>Breast cancer (BC) is a complex and heterogeneous disease including different biological subtypes. This results in molecular and phenotypic heterogeneity within the BC. Stratification of tumors contributed to achieving better outcome in terms of response to therapy and overall survival. Little is known about the features of clonal heterogeneity in different lesion in BC patient. We reported a case of a 52-year-old woman who was diagnosed with luminal B (HER2−) BC and accepted chemotherapy. She achieved partial response based on RECIST 1.1 criteria. However, progressive disease (PD) was then identified with multiple subtypes including luminal B and triple-negative breast cancer (TNBC). Next-generation sequencing (NGS) technologies showed that the different regions of diseased tissue were originated from same clonal genes. We also demonstrated the clonal heterogeneity and gene characterization between lesions of luminal B and TNBC. The patient archived complete remission (CR) with a clear beneficial outcome from immunotherapy treatment. In addition, tumour mutational burden (TMB) and DNA damage repair (DDR) pathway were considered as potential biomarkers for better prediction of tumor immunotherapy efficacy.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000449/pdfft?md5=1b67e5f28be621e38928eedac89505fc&pid=1-s2.0-S2666621924000449-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0